| A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis (NCT06088199) | Amgen | 2023-10-24 |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy (NCT05323617) | Amgen | 2023-08-31 |
| Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone (NCT04586660) | Amgen | 2023-08-17 |
| A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (NCT05975073) | Amgen | 2023-08-01 |
| A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma (NCT05907122) | Amgen | 2023-07-26 |
| Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder (NCT05549258) | Amgen | 2023-07-03 |
| Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (NCT05800964) | Amgen | 2023-06-13 |
| A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (NCT05899816) | Amgen | 2023-06-07 |
| Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (NCT05891119) | Amgen | 2023-06-03 |
| A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (NCT05882877) | Amgen | 2023-05-31 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (NCT05740566) | Amgen | 2023-05-31 |
| Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (NCT05672199) | Amgen | 2023-04-28 |
| Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) (NCT05540665) | Amgen | 2023-04-26 |
| A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (NCT05704738) | Amgen | 2023-04-20 |
| A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants (NCT06674941) | Amgen | 2023-03-24 |
| A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis (NCT05767047) | Amgen | 2023-03-23 |
| Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (NCT03904069) | Amgen | 2023-03-13 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (NCT05317078) | Amgen | 2023-02-28 |
| A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (NCT05724199) | Amgen | 2023-02-21 |
| A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (NCT05633355) | Amgen | 2023-01-30 |
| A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis (NCT05565560) | Amgen | 2023-01-25 |
| A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) (NCT05704725) | Amgen | 2023-01-23 |
| Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus (NCT05669599) | Amgen | 2023-01-18 |
| Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus (NCT05591222) | Amgen | 2022-12-29 |
| A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease (NCT06295679) | Amgen | 2022-12-19 |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial (NCT05581303) | Amgen | 2022-12-14 |
| AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia (NCT05209152) | Amgen | 2022-11-14 |
| EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction (NCT05284747) | Amgen | 2022-10-26 |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (NCT05325866) | Amgen | 2022-09-23 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment (NCT05481411) | Amgen | 2022-09-13 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment (NCT05489614) | Amgen | 2022-09-13 |
| First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT05361395) | Amgen | 2022-08-24 |
| Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity (NCT05406115) | Amgen | 2022-07-26 |
| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease (NCT06389578) | Amgen | 2022-07-14 |
| A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers (NCT05497557) | Amgen | 2022-07-14 |
| Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin (NCT06207682) | Amgen | 2022-06-28 |
| Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study (NCT05430854) | Amgen | 2022-06-01 |
| A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (NCT05398445) | Amgen | 2022-05-31 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (NCT05322577) | Amgen | 2022-05-17 |
| Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata (NCT05368103) | Amgen | 2022-04-27 |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (NCT05198934) | Amgen | 2022-04-19 |
| A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) (NCT05378529) | Amgen | 2022-04-19 |
| A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (NCT05267470) | Amgen | 2022-03-29 |
| A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets (NCT05327491) | Amgen | 2022-03-21 |
| Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (NCT04804553) | Amgen | 2022-03-17 |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (NCT05111626) | Amgen | 2022-03-14 |
| Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) (NCT05174065) | Amgen | 2022-03-08 |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (NCT05052801) | Amgen | 2022-03-07 |
| A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) (NCT05094336) | Amgen | 2022-02-01 |
| Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (NCT04987307) | Amgen | 2022-01-31 |
| A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (NCT04933695) | Amgen | 2022-01-28 |
| A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis (NCT05032066) | Amgen | 2022-01-20 |
| A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (NCT05060016) | Amgen | 2021-12-01 |
| A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) (NCT04478994) | Amgen | 2021-11-17 |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis (NCT04781543) | Amgen | 2021-11-05 |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (NCT04994717) | Amgen | 2021-11-02 |
| A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis (NCT05073315) | Amgen | 2021-10-04 |
| AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (NCT04885998) | Amgen | 2021-09-27 |
| TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study (NCT05002998) | Amgen | 2021-09-16 |
| Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants (NCT05056246) | Amgen | 2021-09-10 |
| Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease (NCT04528082) | Amgen | 2021-09-09 |
| A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease (NCT04583735) | Amgen | 2021-09-02 |
| Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer (NCT04822298) | Amgen | 2021-08-31 |
| Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) (NCT04506086) | Amgen | 2021-08-26 |
| Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants (NCT05045638) | Amgen | 2021-08-20 |
| A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants (NCT05048784) | Amgen | 2021-08-16 |
| Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants (NCT04987333) | Amgen | 2021-08-09 |
| A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants (NCT05909852) | Amgen | 2021-07-23 |
| A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (NCT04948099) | Amgen | 2021-07-06 |
| A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine (NCT04825678) | Amgen | 2021-06-11 |
| A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (NCT04702737) | Amgen | 2021-06-10 |
| Study of VIB7734 for the Treatment of Moderate to Severely Active SLE (NCT04925934) | Amgen | 2021-05-28 |
| A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT04466917) | Amgen | 2021-05-15 |
| Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus (NCT04680637) | Amgen | 2021-05-06 |
| Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (NCT04833855) | Amgen | 2021-04-15 |
| A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT04761627) | Amgen | 2021-03-24 |
| Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy (NCT04772313) | Amgen | 2021-03-08 |
| Aimovig Pregnancy Exposure Registry (NCT06150781) | Amgen | 2021-01-27 |
| A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) (NCT04762498) | Amgen | 2021-01-26 |
| Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta (NCT04545554) | Amgen | 2021-01-21 |
| Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT04631601) | Amgen | 2021-01-15 |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL (NCT04521231) | Amgen | 2021-01-04 |
| A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease (NCT04540497) | Amgen | 2020-12-04 |
| Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients (NCT04590586) | Amgen | 2020-11-24 |
| A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT04607980) | Amgen | 2020-11-11 |
| Biomarker and Genetic Predictors of Erenumab Treatment Response (NCT04265755) | Amgen | 2020-10-26 |
| Myasthenia Gravis Inebilizumab Trial (NCT04524273) | Amgen | 2020-10-15 |
| Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate (NCT04511702) | Amgen | 2020-10-02 |
| Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL (NCT04524455) | Amgen | 2020-10-02 |
| Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia (NCT04478695) | Amgen | 2020-09-29 |
| A Study of TEPEZZA Subcutaneous Administration in Healthy Adults (NCT06563856) | Amgen | 2020-09-22 |
| Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (NCT04252742) | Amgen | 2020-09-15 |
| Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (NCT04362748) | Amgen | 2020-09-15 |
| Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity (NCT04478708) | Amgen | 2020-08-07 |
| Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet (NCT04191616) | Amgen | 2020-08-06 |
| Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study (NCT04270760) | Amgen | 2020-07-28 |
| A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants (NCT05599828) | Amgen | 2020-07-17 |
| Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (NCT04260191) | Amgen | 2020-06-29 |
| A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] (NCT04270747) | Amgen | 2020-06-22 |
| Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). (NCT04303780) | Amgen | 2020-06-04 |